Blood Test Tracks Alzheimer Markers Beyond p-tau217
Researchers benchmarked newly available plasma p-tau205 and p-tau212 immunoassays against p-tau217 for identifying Alzheimer disease pathophysiology.
Updated on Nov. 9, 2026 in Alzheimer’s

Researchers compared newly available blood-based p-tau205 and p-tau212 immunoassays with p-tau217, the leading p-tau biomarker measurable in blood. The study analyzed participants from the Heart Strategies Concentrating on Risk Evaluation cohort and the University of Pittsburgh AD Research Center.
Why it matters
Plasma p-tau217 is currently the leading blood-based marker for Alzheimer disease, so additional markers could broaden how the disease is identified. The findings suggest p-tau212 may offer a complementary or alternative option where p-tau217 is unavailable.
The biomarker comparison used Pearson correlations across research cohorts, with p-tau212 and p-tau217 correlating at r=0.52-0.78 and p-tau212 showing r=0.38-0.54 with Aβ-PET uptake versus r=0.19-0.43 for p-tau217. Whether these correlations hold in larger or more diverse populations has not been established.
The players
University of Pittsburgh Alzheimer's Disease Research Center
A research center at the University of Pittsburgh that studies Alzheimer disease and contributed participants to the biomarker analysis.
Heart Strategies Concentrating on Risk Evaluation (HABS-HD) cohort
A longitudinal research cohort whose participants were included in the plasma biomarker comparison.
The details
Plasma p-tau212 and p-tau217 were first elevated in individuals who were amyloid-positive and tau-negative, while plasma p-tau205 became abnormal only in individuals who were positive for both amyloid and tau. Trajectory modeling showed p-tau212 crossed the 1.5 SD threshold earliest for both Aβ-PET and tau, followed closely by p-tau217, while p-tau205 did not cross this threshold.
Timeline
Article on the plasma p-tau biomarker study was published November 9, 2026.
Biomarker Landscape
Plasma p-tau217 is the leading p-tau biomarker measurable in blood, and this study tests whether newer p-tau205 and p-tau212 assays can match or complement it. The comparison positions p-tau212 as a possible alternative where p-tau217 testing is not available.
Blood-based tests may eventually offer a less invasive way to screen for Alzheimer disease pathology than imaging or spinal fluid testing. The study does not indicate that these assays are currently available for routine clinical use.
The takeaway
Blood-based biomarkers are expanding beyond p-tau217, and p-tau212 showed early and strong associations with Alzheimer pathology in this comparison. Readers should watch for further validation before these markers are used in clinical practice.
Further reading
Explore more research on Alzheimer’s biomarkers and diagnostic tools.



